Collaborative Research and Licensing Opportunity: Polyvalent Influenza Virus-Like Particles (VLPs) and Their Use as Vaccines

This virus-like particle (VLP) vaccine technology for influenza viruses may be utilized for the development of an universal influenza virus vaccine.

Like Comment

This virus-like particle (VLP) vaccine technology for influenza viruses, based on a mixture of VLPs expressing the hemagglutinin protein or the neuraminidase protein from influenza virus strains belonging to different virus subtypes, has demonstrated broad protection against lethal challenge in mice with various influenza virus strains and virus subtypes. Results from ferret and mouse studies demonstrate broad heterosubtypic protection against various influenza virus subtypes further supporting and strengthening the proposed application of this technology as a universal influenza virus vaccine.

Potential Commercial Applications:

• Universal Flu Vaccine

Competitive Advantages:

  • broad/universal protection against influenza viruses
  • does not require reformulating vaccine each year as is currently necessary with vaccines available on the market
  • can potentially provide protection against novel influenza viruses that may arise in the future, including potentially pandemic influenza viruses


Schwartzman, et al. An Intranasal Virus-Like Particle Vaccine Broadly Protects Mice from Multiple Subtypes of Influenza A Virus. 2015. MBio. 6(4): e01044-15.

Intellectual Property: U.S. Provisional Application No. 62/014,814; PCT/US2015/029843 (HHS Reference No. E-195-2014)

Collaborative Research Opportunity:The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this invention, especially for GMP manufacture and clinical evaluation.

Contact: Dr. Jenish Patel, tel. (240) 669-2894,

Go to the profile of NIAID Technology Transfer and Intellectual Property Office

NIAID Technology Transfer and Intellectual Property Office

NIAID’s technology transfer office, TTIPO, is a one-stop resource for organizations interested in partnering with NIAID to access, develop, and manage the translation of research discoveries into medically beneficial products. TTIPO seeks to expand NIAID’s innovation pipeline with existing and new partners in areas such as newly emerging and re-emerging infectious diseases (e.g., dengue, Zika, Ebola, influenza, methicillin-resistant Staphylococcus aureus and HIV/AIDS), biodefense (e.g., smallpox and anthrax), and immune-mediated diseases (e.g., asthma and allergy).

No comments yet.